18546317. COMPOSITIONS AND METHODS FOR INHIBITING KRAS simplified abstract (LAWRENCE LIVERMORE NATIONAL SECURITY, LLC)

COMPOSITIONS AND METHODS FOR INHIBITING KRAS

Organization Name

LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

Inventor(s)

Bin Wang of Dallas TX (US)

Rui Xu of Dallas TX (US)

Eli Wallace of Loveland CO (US)

Felice Lightstone of Fremont CA (US)

Yue Yang of Foster City CA (US)

Paola Bisignano of San Francisco CA (US)

Anna Elzbieta Maciag of Frederick MD (US)

David Michael Turner of Frederick MD (US)

Dhirendra Kumar Simanshu of Frederick MD (US)

Albert Hay Wah Chan of Frederick MD (US)

Zuhui Zhang of Millbrae CA (US)

Christopher John Brassard of Frederick MD (US)

Tao Liao of Frederick MD (US)

COMPOSITIONS AND METHODS FOR INHIBITING KRAS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18546317 titled 'COMPOSITIONS AND METHODS FOR INHIBITING KRAS

• • Simplified Explanation:**

The patent application discusses compounds and pharmaceutical compositions for modulating KRAS and treating diseases like cancer.

• • Key Features and Innovation:**
• Compounds of formula (I) and (II) for inhibiting KRAS mutations.
• Pharmaceutical compositions containing these compounds.
• Methods for treating diseases by modulating KRAS.

• • Potential Applications:**

The technology can be applied in the treatment of various cancers and other diseases associated with KRAS mutations.

• • Problems Solved:**

The technology addresses the need for effective treatments targeting KRAS mutations, which are common in cancer.

• • Benefits:**
• Improved treatment options for patients with KRAS-mutated cancers.
• Potential for personalized medicine based on specific mutations.

• • Commercial Applications:**

The technology has significant commercial potential in the pharmaceutical industry for developing targeted therapies for cancer treatment.

• • Questions about KRAS:**

1. What are the challenges in targeting KRAS mutations in cancer treatment? 2. How do these compounds specifically modulate KRAS mutations?

• • Frequently Updated Research:**

Researchers are continually exploring new compounds and strategies for targeting KRAS mutations in cancer therapy. Stay updated on the latest advancements in this field for potential breakthroughs in treatment options.

Original Abstract Submitted

Provided herein are compounds of formula (I) and (II), or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e.g., inhibiting) KRAS (e.g., KRAS having a G12D mutation) and treating diseases or disorders such as cancers in subjects in need thereof.